Immunological effects of a novel RNA-based adjuvant in liver cancer patients.

ABSTRACT: Evaluation of biological effects of adjuvants on immune cells has been assessed in a limited number of studies. Moreover, no data are available on samples derived from cancer patients who may have a severe immune impairment. The effects of a novel RNA-based adjuvant (RNAdjuvant^® developed by CureVac) were assessed in an ex vivo setting on PBMCs obtained from 8 healthy volunteers and 17 HCC patients, using a multiparametric approach to analyze network dynamics of early immune responses. Evaluation of CD80, CD86 and HLA-DR expression, cytokine production as well as gene expression was performed. Moreover, the downstream effect on CD4⁺ T cell phenotyping was evaluated. Treatment with RNAdjuvant^® showed comparable effects on PBMCs of both HCC and healthy subjec

SUBMITTER: Circelli L 

PROVIDER: S-EPMC11028778 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature